Feedback

Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

Affiliation
Schools of Laboratory Medicine and Bioengineering ,Hangzhou Medical College ,Hangzhou ,Zhejiang Province ,China
Jing, Jia;
Affiliation
Women’s Hospital ,School of Medicine ,Zhejiang University ,Hangzhou ,Zhejiang Province ,China
Rui, Li;
Affiliation
Schools of Laboratory Medicine and Bioengineering ,Hangzhou Medical College ,Hangzhou ,Zhejiang Province ,China
Junyuan, Sun;
Affiliation
School of Pharmacy ,Hangzhou Medical College ,Hangzhou ,Zhejiang Province ,China
Jinfeng, Yang;
Affiliation
School of Pharmacy ,Hangzhou Medical College ,Hangzhou ,Zhejiang Province ,China
Zhihao, Hong;
Affiliation
Women’s Hospital ,School of Medicine ,Zhejiang University ,Hangzhou ,Zhejiang Province ,China
Weiguo, Lu;
Affiliation
Institute of Occupation Diseases ,Hangzhou Medical College ,Hangzhou ,Zhejiang Province ,China
Zhenyu, Jia

S-phase kinase-associated protein 2 (Skp2) is a substrate-specific adaptor in Skp1-CUL1-ROC1-F-box E3 ubiquitin ligases and widely regarded as an oncogene. Therefore, Skp2 has remained as an active anticancer research topic since its discovery. Accordingly, the structure of Skp2 has been solved and numerous Skp2 inhibiting compounds have been identified. In this review, we would describe the structural features of Skp2, introduce the ubiquitination function of SCF Skp2 , and summarize the diverse natural and synthetic Skp2 inhibiting compounds reported to date. The IC 50 data of the Skp2 inhibitors or inhibiting compounds in various kinds of tumors at cellular levels implied that the cancer type, stage and pathological mechanisms should be taken into consideration when selecting Skp2-inhibiting compound for cancer treatment.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Jing, Rui, Junyuan, Jinfeng, Zhihao, Weiguo and Zhenyu.

Use and reproduction: